Spike Protein News and Research

RSS

“React and inject”: synthetic peptide-modified nanodiamonds as emergency pan-coronavirus vaccines

A recent study published in the MDPI journal, Pathogens, describes a coronavirus peptide vaccine antigen in the form of nanodiamond-based formulations, that demonstrated a robust and long-lasting immune response. The nanodiamonds proved to be a powerful and versatile platform for antigen conjugation. This could make it a safe and effective strategy for the production of off-the-shelf vaccines against multiple coronaviruses.

13 Jul 2021

Review details clinical signs of SARS-CoV-2 infection in domestic and wild cats

Now, a new systematic review has been published in the journal Animals that focuses on the clinical symptoms in felines diagnosed with SARS-CoV-2 worldwide.

13 Jul 2021

Natural compound 'pheophorbide a' demonstrates robust antiviral activity against SARS-CoV-2 in vitro

A team of scientists from France has recently demonstrated photosensitive antiviral activity of the natural compound pheophorbide a (Pba) against a broad range of enveloped viruses, including coronaviruses.

12 Jul 2021

New research examines the elimination of the B.1.362 + L452R variant in Israel

Is it possible to completely get rid of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants? New research led by Neta S. Zuckerman of Sheba Medical Center in Israel suggests it’s possible. Their report details the upsurge of a B.1.362 variant harboring the L452R mutation that eventually disappeared due to vaccination efforts and the presence of more robust variants.

12 Jul 2021

Scientists identify novel entry receptors for SARS-CoV-2

Scientists from the Northeastern University, China, and University of Michigan, USA, have recently identified five potential entry receptors for SARS-CoV-2. These receptors specifically express in SARS-CoV-2-infected cells and have a high binding affinity for the viral spike protein.

12 Jul 2021

mRNA-based COVID-19 vaccine CV07050101 demonstrates limited immunogenicity in non-human primates

Scientists from the US and Germany have recently evaluated the efficacy of an mRNA-based COVID-19 vaccine candidate, CV07050101, in inducing humoral and cellular immune responses in non-human primates. The study reveals that prime-boost immunization with the vaccine candidate induces only limited immunity against SARS-CoV-2.

12 Jul 2021

Novel monoclonal antibody could pave way for future COVID-19 treatments and vaccines

Researchers in the United States have shown that targeting the N-terminal domain (NTD) of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) viral spike protein could achieve broad neutralization of variants of concern.

11 Jul 2021

Scientists analyze the sensitivity of SARS-CoV-2 Delta variant to monoclonal antibodies

The Delta variant was detected for the first time in India in October 2020 and has since spread throughout the world.

9 Jul 2021

New York City SARS-CoV-2 breakthrough cases predominantly Alpha and Iota variants

While Delta (B.1.617.2) has overtaken Alpha (B.1.1.7) as the dominant severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variant in the United States, Alpha remained a force to be reckoned with in New York City earlier this year. New research published on the preprint medRxiv* server details breakthrough infections in vaccinated and unvaccinated individuals living in New York City.

9 Jul 2021

Durable antibody response at least 8 months following vaccination with J&J COVID vaccine

A recent study by a team of scientists at Beth Israel Deaconess Medical Center and Janssen Vaccines & Prevention has demonstrated that humoral and cellular immunity elicited by the coronavirus disease 2019 (COVID-19) vaccine Ad26.COV2.S remains active for at least eight months.

9 Jul 2021

Why is the SARS-CoV-2 Delta variant so concerning?

As cases surge in the United States, health experts have raised the alarm that vaccinated individuals may be spreading the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Delta variant. Over half of new infections in the U.S. are now caused by this highly transmissible variant.

9 Jul 2021

SARS-CoV-2 antibody testing in oral fluids may be an efficient way forward for research in children

A recent study by researchers from the United Kingdom (UK) and Brazil shows how laboratory assays based on the detection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibodies in oral fluids can be used as a suitable tool for population-based seroepidemiology studies in children. The paper is currently available on the medRxiv* preprint server while it undergoes peer review.

8 Jul 2021

Breakthrough SARS-CoV-2 infection among fully vaccinated likely to be less transmissible

Researchers in the United States have conducted a study suggesting that individuals fully vaccinated against coronavirus disease 2019 (COVID-19) who develop breakthrough infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are less likely to transmit the virus to others than unvaccinated infected individuals.

8 Jul 2021

Early B cell signatures predict antibody responses to mRNA-based COVID-19 vaccine

Researchers in the United States have identified both antigen-specific and antigen non-specific predictive signatures of antibody responses to Moderna’s two-dose coronavirus disease 2019 (COVID-19) vaccine that protects against infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

8 Jul 2021

Intranasal COVID-19 vaccine protects animals against lethal COVID-19 infection

In a new study assessing the potential of a single-dose, intranasal COVID-19 vaccine, a team from the University of Iowa and the University of Georgia found that the vaccine fully protects mice against lethal COVID-19 infection.

8 Jul 2021

Instant biosensor can detect COVID-19 variants even if someone is asymptomatic

RMIT University is collaborating with partners including Australian biomedical start-up Soterius on the biosensor, which can detect the presence of tiny amounts of the SARS-CoV-2 virus and its variants.

8 Jul 2021

How do host factors like the lung microbiome aid in SARS‐CoV‐2 infection?

A new article has been published in Cellular and Molecular Lifesciences, which focuses on the connection between host factors and the worsening of the COVID-19. Further, the impact of the virus on the host’s microbiome and secondary infection has also been studied.

8 Jul 2021

Growing concern over SARS-CoV-2 Lambda variant

A new report from Chile – currently available on the medRxiv* preprint server – reveals how mutations in the spike glycoprotein of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Lambda variant can confer protection from neutralizing antibodies and increase viral infectivity rates, which means massive vaccination campaigns should be accompanied by strict genomic surveillance.

8 Jul 2021

Striking increase in SARS-CoV-2 antibodies seen with prime dose AstraZeneca vaccine followed by Pfizer-BioNTech

Researchers in Germany have provided evidence that a booster shot of a messenger RNA (mRNA)-based coronavirus disease 2019 (COVID-19) vaccine following prime immunization with AstraZeneca’s adenoviral vector-based vaccine is sufficient to achieve high levels of neutralizing antibodies against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

8 Jul 2021

How SARS-CoV-2 has evolved over the course of the pandemic

In an effort to understand the ongoing evolution of the SARS-CoV-2 genome, researchers constructed a phylogenetic tree of all available SARS-CoV-2 genomes.

7 Jul 2021

Spike Protein News and Research

“React and inject”: synthetic peptide-modified nanodiamonds as emergency pan-coronavirus vaccines

Review details clinical signs of SARS-CoV-2 infection in domestic and wild cats

Natural compound 'pheophorbide a' demonstrates robust antiviral activity against SARS-CoV-2 in vitro

New research examines the elimination of the B.1.362 + L452R variant in Israel

Scientists identify novel entry receptors for SARS-CoV-2

mRNA-based COVID-19 vaccine CV07050101 demonstrates limited immunogenicity in non-human primates

Novel monoclonal antibody could pave way for future COVID-19 treatments and vaccines

Scientists analyze the sensitivity of SARS-CoV-2 Delta variant to monoclonal antibodies

New York City SARS-CoV-2 breakthrough cases predominantly Alpha and Iota variants

Durable antibody response at least 8 months following vaccination with J&J COVID vaccine

Why is the SARS-CoV-2 Delta variant so concerning?

SARS-CoV-2 antibody testing in oral fluids may be an efficient way forward for research in children

Breakthrough SARS-CoV-2 infection among fully vaccinated likely to be less transmissible

Early B cell signatures predict antibody responses to mRNA-based COVID-19 vaccine

Intranasal COVID-19 vaccine protects animals against lethal COVID-19 infection

Instant biosensor can detect COVID-19 variants even if someone is asymptomatic

How do host factors like the lung microbiome aid in SARS‐CoV‐2 infection?

Growing concern over SARS-CoV-2 Lambda variant

Striking increase in SARS-CoV-2 antibodies seen with prime dose AstraZeneca vaccine followed by Pfizer-BioNTech

How SARS-CoV-2 has evolved over the course of the pandemic

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest News